Product Description: Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations[1].
Applications: Metabolism-sugar/lipid metabolism
Formula: C28H36N2O8
References: [1]Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273./[2]Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655.
CAS Number: 1661838-94-3
Molecular Weight: 528.59
Compound Purity: 99.43
Research Area: Metabolic Disease
Solubility: DMSO : 200 mg/mL (ultrasonic)
Target: SGLT
Deutsch
English
